Drug stops multiple sclerosis - but sufferers can't get it!

Cris Kerr highlights Naltrexone in her latest issue of 'Case Health - Health Success Stories'.

Naltrexone is traditionally used to help people who have a narcotic or alcohol addiction stay drug free. Naltrexone is used after the patient has stopped taking drugs or alcohol. It works by blocking the effects of narcotics or by decreasing the craving for alcohol. U.S. National Library of Medicine

Cris recently became aware of a drug that appeared to stop the progression of Multiple Sclerosis, potentially enhancing the quality of life of many Multiple Sclerosis (MS) sufferers.

The drug is Naltrexone (also known as ReVia) and Cris's 'Health Success Stories' database contains a growing body of compelling anecdotal evidence that Low Dose Naltrexone (LDN) works, and; it works well - BUT, sufferers can't get it.

"Naltrexone has not achieved mainstream acceptance as a treatment option for MS due to absence of clinical trial data. Research, drug development, and clinical trials are commercially-driven by sponsors. That's okay, but there's no recognized body that can officially step up to the plate to speak and act on behalf of patients. I know this because I've tried, without success, to find an authority that is sanctioned to do so."

The present system is inequitable. It doesn't place sufficient value on patient health success stories. It doesn't place sufficient value on advocating for the patient. It doesn't place sufficient value on patient-driven research or clinical trials. If it did, there would be a body sanctioned to speak and act on a promising body of patient testimonials.

How many stories similar to the LDN story are out there? We don't know, because they haven't all been collected, stored, and shared. That makes me feel uneasy and should make you feel uneasy.

We need an organisation chartered to act on this type of evidence; an organisation that values patient testimony and can make recommendations (without prejudice) on behalf of patients from all corners of the globe.

About the author

Cris Kerr created the 'Case Health - Health Success Stories' community website in 2001. The website collects and shares health success stories (cure or improved quality of life) attributed to any treatment.

Stories are added to an online database with keywords so visitors can search the database by symptom, condition, or treatment. Though based in Australia, the site holds stories and selected research articles from all over the world and the service is provided totally free of any charge.

Evidence-based medicine seeks to make successful outcomes sustainable and repeatable by first recording evidence of successful outcomes, then sharing this evidence with others to enhance the number of successful outcomes.

Cris believes the patient is best-placed to attest health success. “Health systems throughout the world have long overlooked patient testimony. I advocate the value of health success stories in the public's interest, and to promote the need for a more equitable health system.”

“Governments throughout the world could prove they value and give credence to patient testimony by implementing official bodies and processes chartered to act on compelling evidence in the form of health success stories.”

To read ‘DRUG STOPS MULTIPLE SCLEROSIS - BUT SUFFERERS CAN'T GET IT' or search for other health success stories visit the ‘Case Health – Health Success Stories' website and search the database.

Comments

  1. Bonnie A. Shockey Bonnie A. Shockey United States says:

    This article by Chris Kerr, written in or posted to RealAge, was in 2005.  Low dose naltrexone (LDN) therapy has grown in leaps and bounds in 4 1/2 years.  LDN (an off-label use of a FDA approved drug - naltrexone) IS now available through a doctor's prescription which can be filled at a compounding pharmacy. But...the patient may have to be proactive and educate her/his doctor to the benefits of LDN. It is being used worldwide and there are now thousands of anecdotal experiences which seem to validate the theory that LDN does work and appears to possibly work in almost all autoimmune diseases, HIV/AIDS, Lyme disease, and pancreatice cancer.  Please read the most comprehensive book yet written on LDN by Elaine Moore called The Promise of Low Dose Naltrexone Thereapy.  Visit the following Web sites for more information.  www.ldninfo.org, www.revolutionhealth.com, www.webspawner.com/users/introtoldn, www.ldners.org, www.lowdosenaltrexone.org, www.autoimmunedisease.suite101.com, www.gazorpa.com

  2. Cris Kerr Cris Kerr Australia says:

    Thank you Bonnie.

    The Case Health website closed in 2009, but I have continued with my free book 'Those Who Suffer Much, Know Much', and the 2010 edition has just been released (see below).

    ###

    'Those Who Suffer Much, Know Much' 2010 edition
    by Cris Kerr

    My 2010 5th book revision contains 51 patient testimonies of health success presented as case studies, an explanatory article, and interviews with 19 professionals familiar with this treatment:

    The 2010 edition is available free of charge or expectation from the LDN Research Trust website in the UK (**free Acrobat Reader 9
    required): www.ldnresearchtrustfiles.co.uk/docs/2010.pdf

    The first article in the book is an easy read and I commend it to anyone who wants to better understand how it is that patient's can be denied a treatment that's working for others, even after all other treatment options have failed.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study links initial symptoms to long-term disability in multiple sclerosis